AIP
BBIO icon

Ameritas Investment Partners’s BridgeBio Pharma BBIO Stock Holding History

Ameritas Investment Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,988
Closed -$964K – 3190
2026
Q1 		$964K Sell
12,988
-116
-0.9% -$8.41K 0.03% 615
2025
Q4 		$1M Buy
13,104
+40
+0.3% +$2.63K 0.03% 611
2025
Q3 		$679K Sell
13,064
-2,902
-18% -$142K 0.02% 720
2025
Q2 		$689K Buy
15,966
+1,635
+11% +$59.5K 0.02% 730
2025
Q1 		$495K Sell
14,331
-375
-3% -$12.6K 0.02% 820
2024
Q4 		$404K Buy
14,706
+466
+3% +$12K 0.01% 939
2024
Q3 		$363K Buy
14,240
+468
+3% +$12.3K 0.01% 972
2024
Q2 		$349K Buy
13,772
+2,232
+19% +$61K 0.01% 944
2024
Q1 		$357K Hold
11,540
– – 0.01% 945
2023
Q4 		$466K Buy
11,540
+161
+1% +$4.83K 0.02% 825
2023
Q3 		$300K Buy
11,379
+1,922
+20% +$54.5K 0.01% 957
2023
Q2 		$163K Buy
9,457
+1,257
+15% +$18.9K 0.01% 1262
2023
Q1 		$136K Hold
8,200
– – 0.01% 1323
2022
Q4 		$69.9K Hold
8,200
– – ﹤0.01% 1833
2022
Q3 		$81K Hold
8,200
– – ﹤0.01% 1646
2022
Q2 		$74K Hold
8,200
– – ﹤0.01% 1706
2022
Q1 		$83K Hold
8,200
– – ﹤0.01% 1758
2021
Q4 		$137K Sell
8,200
-238
-3% -$10.1K ﹤0.01% 1491
2021
Q3 		$395K Hold
8,438
– – 0.01% 861
2021
Q2 		$514K Buy
8,438
+785
+10% +$44.8K 0.02% 785
2021
Q1 		$471K Buy
7,653
+1,447
+23% +$94.7K 0.02% 800
2020
Q4 		$441K Hold
6,206
– – 0.02% 799
2020
Q3 		$233K Sell
6,206
-272
-4% -$8.56K 0.01% 957
2020
Q2 		$211K Hold
6,478
– – 0.01% 996
2020
Q1 		$188K Buy
6,478
+4,600
+245% +$143K 0.01% 966
2019
Q4 		$66K Hold
1,878
– – ﹤0.01% 1750
2019
Q3 		$40K Buy
+1,878
New +$52K ﹤0.01% 2008

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Ameritas Investment Partners's BBIO Position: Q2 2026 in Review

Ameritas Investment Partners sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 12,988 shares — an estimated $964K sold.

Ameritas Investment Partners first reported a position in BBIO in Q3 2019 and held it in 27 quarters. The position peaked at $1M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Ameritas Investment Partners reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Ameritas Investment Partners sold 12,988 BridgeBio Pharma shares in Q2 2026, an estimated $964K.
  • Ameritas Investment Partners first reported a position in BridgeBio Pharma in Q3 2019 and held it in 27 quarters.
  • Ameritas Investment Partners's BridgeBio Pharma position peaked at $1M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.